1 Barrios V, Escobar C, Caldero  ́n A, Llisterri JL, Alegr  ́a E, Mun  ̃ iz J et al. Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low- density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr 2007; 2: 9–15.
2 Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817–1822.
3 Liu SJ, Guo ZR, Hu XS, Wu M, Chen FM, Kang GD et al. Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up. Diabetes Res Clin Pract 2008; 81: 117–123.
4 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta- analysis. Lancet 2007; 369: 201–207.
5 Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens 2008; 10: 27–32.
6 Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18: 308–347.
7 Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J. STAR investigators. differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–2597.
8 Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two-armed study in 14 200 patients. Cardiovasc Diabetol 2007; 6: 12.
9 Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008; 149: 307–316.
10 Sjo  ̈holm A, Nystro  ̈m T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 4–10.
11 Rubin D, Claas S, Pfeuffer M, Nothnagel M, Foelsch UR, Schrezenmeir J. s-ICAM-1 and s-VCAM- 1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal. Lipids Health Dis 2008; 7: 32.
12 Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–1336.
13 Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterios- cler Thromb Vasc Biol 2003; 23: 2155–2163.
14 Fogari R, Preti P, Zoppi A, Mugellini A, Corradi L, Lazzari P, Santoro T, Derosa G. Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med 2008; 47: 1851–1857.
15 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059–1062.
16 Hansson L, Hedner T, Dahlo  ̈f B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1: 113–119.
17 WHO/International Diabetes Consultation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyper- glycaemia. WHO: Geneva, Switzerland, 2006, 46pp.
18 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–1495.
19 Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–1431.
20 Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290–300.
21 Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587–604.
22 Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7: 229–239.
23 De Pablos-Velasco PL, Mart  ́nez-Mart  ́n FJ, Rodr  ́guez- P  ́rez F. Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the Gu  ́a Study. Eur J Clin Nutr 2002; 56: 557–560.
24 Borch-Johnsen K, Wareham N. The rise and fall of the metabolic syndrome. Diabetologia 2010; 53: 597–599.
25 Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr 2007; 2: 104–107.
26 Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426.
27 Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Reduction in 
28 Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P et al. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009; 11: 177–187.
29 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
30 Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension 2009; 54: 951–953.
31 Eriksson JW, Jansson PA, Carlberg B, H  ̈gg A, Kurland L, Svensson MK et al. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) study. Hypertension 2008; 52: 1030–1037.
32 Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010; 55: 61–68.
33 Alderman MH. New-onset diabetes during antihypertensive therapy. Am J Hypertens 2008; 21: 493–499.
34 Alderman MH. Is new-onset diabetes mellitus impor- tant? Yes, buty. High Blood Pres & Cardiovasc Prev 2008; 15: 5–8.
35 Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr 2008; 3: 18–25.
36 Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ et al. Newly diagnosed and previously known diabetes mellitus and 1–year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572–1578.
37 Jamerson K, Weber MA, Bakris GL, Dahlo  ̈ f B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–2428.
38 Matsui Y, Eguchi K, O 0 Rourke MF, Ishikawa J, Miyashita H, Shimada K et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54: 716–723.
39 Fliser D, Buchholz K, Haller H. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertension patients with microinflammation. Circulation 2004; 110: 1103–1107.
40 Smith DH, Neutel JM, Lacourci `re Y, Kempthorne- Rawson J. Prospective, randomized, open-label, blinded- endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21: 1291–1298. This work is licensed under the Creative Commons Attribution-NonCommercial-